{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:28:20Z","timestamp":1761294500720,"version":"build-2065373602"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) SAVE programme","award":["75N93021C00014","75N93021C00014","75N93021C00014","75N93021C00014","75N93021C00014"],"award-info":[{"award-number":["75N93021C00014","75N93021C00014","75N93021C00014","75N93021C00014","75N93021C00014"]}]},{"DOI":"10.13039\/501100005370","name":"Gates Cambridge Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005370","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Research Council","award":["MR\/Y004337\/1","MR\/Y004337\/1","MR\/Y004337\/1"],"award-info":[{"award-number":["MR\/Y004337\/1","MR\/Y004337\/1","MR\/Y004337\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The rapid spread of the Omicron BA.1 (B.1.1.529.1) SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) variant in 2021 resulted in international efforts to quickly assess its escape from immunity generated by vaccines and previous infections. Numerous laboratories published BA.1 neutralization data as preprints and reports. We collated this data in real time and regularly presented updates of the aggregated results in US, European and WHO research and advisory settings. Here, we retrospectively analyzed the accuracy of these aggregations from 85 different sources published during a time period from 2021\/12\/08 up to 2022\/08\/14. We found that the mean titer fold change from wild type-like variants to BA.1, a standard measure of a variant\u2019s immune escape, remained stable after the first 15 days of data reporting in people who were twice vaccinated, and incoming data increased the confidence in this quantity. Further, it is possible to build reliable, stable antigenic maps from this collated data already after one month of incoming data. We here demonstrate that combining early reports from variable, independent sources can rapidly indicate a new virus variant\u2019s immune escape and can therefore be of immense benefit for public health.<\/jats:p>","DOI":"10.1038\/s41598-025-19578-3","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:23:48Z","timestamp":1761294228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-2382","authenticated-orcid":false,"given":"Antonia","family":"Netzl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7342-9295","authenticated-orcid":false,"given":"Sina","family":"T\u00fcreli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-5693","authenticated-orcid":false,"given":"Eric B.","family":"LeGresley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-8530","authenticated-orcid":false,"given":"Barbara","family":"M\u00fchlemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7760-8474","authenticated-orcid":false,"given":"Samuel H.","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-1890","authenticated-orcid":false,"given":"Derek J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"19578_CR1","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"19578_CR2","unstructured":"Netzl, A. et al. Aggregated Omicron neutralization data (last update 2022-05-26). https:\/\/docs.google.com\/presentation\/d\/13NFT3GjMluTbDQZRSl7VIua6G3FvwSHYgbU9gMoWI4U."},{"key":"19578_CR3","unstructured":"Netzl, A. N. et al. - Collected Omicron antigenic data - Google Sheets. https:\/\/docs.google.com\/spreadsheets\/d\/1IvUwoWMAtJULnN-pohUoPio0RmHZIRj8OTtv9r4RFl4\/edit?gid=0#gid=0."},{"key":"19578_CR4","doi-asserted-by":"crossref","unstructured":"Bernal, J.\u00a0L. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine 385, 585\u2013594 (2021). https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2108891. Publisher: Massachusetts Medical Society _eprint: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2108891","DOI":"10.1056\/NEJMc2113090"},{"key":"19578_CR5","unstructured":"EtR for Use of COVID-19 Vaccine Booster Doses | CDC (2024). https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/covid-19-booster-doses-etr.html."},{"key":"19578_CR6","unstructured":"JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022. https:\/\/www.gov.uk\/government\/publications\/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022\/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022."},{"key":"19578_CR7","unstructured":"Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467\u2013484.e15 (2022). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0092867421015786."},{"key":"19578_CR8","unstructured":"COVID-19 Variant of Concern Omicron (B.1.1.529): Risk Assessment, January 12, 2022. Risk Assessment (2022)."},{"key":"19578_CR9","unstructured":"WHO. WHO Global Weekly Epidemiological Updates on COVID-19 -April 2022.pdf. https:\/\/www.thehinducentre.com\/resources\/article38483650.ece\/binary\/WHO%20Global%20Weekly%20Epidemiological%20Updates%20on%20COVID-19%20-April%202022.pdf."},{"key":"19578_CR10","unstructured":"WHO. Weekly_epidemiological_update_-_coronavirus_disease_covid-19_84_who_22mar2022.pdf. https:\/\/themimu.info\/sites\/themimu.info\/files\/documents\/Weekly_Epidemiological_Update_-_Coronavirus_Disease_COVID-19_84_WHO_22Mar2022.pdf."},{"key":"19578_CR11","unstructured":"Gilbert, P.\u00a0B. et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial (2021). https:\/\/www.medrxiv.org\/content\/10.1101\/2021.08.09.21261290v4. Pages: 2021.08.09.21261290."},{"key":"19578_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 27, 2032\u20132040 (2021).","journal-title":"Nature Medicine"},{"key":"19578_CR13","unstructured":"on COVID-19 Vaccine Composition (TAG-CO-VAC), T. A.\u00a0G. Interim statement on the composition of current COVID-19 vaccines (2022). https:\/\/www.who.int\/news\/item\/17-06-2022-interim-statement-on--the-composition-of-current-COVID-19-vaccines."},{"key":"19578_CR14","unstructured":"Weirr, J.\u00a0P. Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Presentation- COVID19 Vaccine Strain Composition (2022). https:\/\/www.fda.gov\/media\/159495\/download."},{"key":"19578_CR15","unstructured":"Garcia-Beltran, W.\u00a0F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.\u00a02021.12.14.21267755. (2021). https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.14.21267755v1."},{"key":"19578_CR16","doi-asserted-by":"crossref","unstructured":"Zhou, R. et al. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2 (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.05.09.491254.","DOI":"10.22541\/au.165237518.80150889\/v1"},{"key":"19578_CR17","doi-asserted-by":"crossref","unstructured":"Seki, Y. et al. Safety and immunogenicity of Pfizer\/BioNTech SARS-CoV-2 mRNA third booster vaccine against SARS-CoV-2 Omicron variant in Japanese healthcare workers (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.20.22269587.","DOI":"10.1101\/2022.01.20.22269587"},{"key":"19578_CR18","unstructured":"Edara, V.-V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.20.473557."},{"key":"19578_CR19","doi-asserted-by":"crossref","unstructured":"Wilks, S.\u00a0H. et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382, eadj0070 (2023). https:\/\/www.science.org\/doi\/10.1126\/science.adj0070.","DOI":"10.1126\/science.adj0070"},{"key":"19578_CR20","doi-asserted-by":"crossref","unstructured":"Smith, D.\u00a0J. et al. Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science 305, 371\u2013376 (2004). https:\/\/www.science.org\/doi\/10.1126\/science.1097211.","DOI":"10.1126\/science.1097211"},{"key":"19578_CR21","unstructured":"Branche, A.\u00a0R. et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nature Medicine 29, 2334\u20132346 (2023). https:\/\/www.nature.com\/articles\/s41591-023-02503-4."},{"key":"19578_CR22","doi-asserted-by":"crossref","unstructured":"R\u00f6ssler, A. et al. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nature Communications 14, 5224 (2023). https:\/\/www.nature.com\/articles\/s41467-023-41049-4.","DOI":"10.1038\/s41467-023-41049-4"},{"key":"19578_CR23","unstructured":"Fonville, J.\u00a0M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996\u20131000 (2014). https:\/\/www.science.org\/doi\/10.1126\/science.1256427."},{"key":"19578_CR24","doi-asserted-by":"publisher","unstructured":"Hu, B. et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerging Microbes & Infections 11, 2275\u20132287 (2022). Publisher: Taylor & Francis _ eprint: https:\/\/doi.org\/10.1080\/22221751.2022.2117098","DOI":"10.1080\/22221751.2022.2117098"},{"key":"19578_CR25","doi-asserted-by":"crossref","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S.\u00a0A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunological Reviews 310, 6\u201326 (2022). https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imr.13091. Publisher: John Wiley & Sons, Ltd.","DOI":"10.1111\/imr.13091"},{"key":"19578_CR26","doi-asserted-by":"crossref","unstructured":"Brady, C. et al. A systems biology approach to define SARS-CoV-2 correlates of protection. npj Vaccines 10, 69 (2025). https:\/\/www.nature.com\/articles\/s41541-025-01103-2. Publisher: Nature Publishing Group.","DOI":"10.1038\/s41541-025-01103-2"},{"key":"19578_CR27","unstructured":"Sun, K. et al. SARS-CoV-2 correlates of protection from infection against variants of concern. Nature Medicine 30, 2805\u20132812 (2024). https:\/\/www.nature.com\/articles\/s41591-024-03131-2. Publisher: Nature Publishing Group."},{"key":"19578_CR28","doi-asserted-by":"crossref","unstructured":"Earle, K.\u00a0A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X21006587.","DOI":"10.1016\/j.vaccine.2021.05.063"},{"key":"19578_CR29","doi-asserted-by":"crossref","unstructured":"R\u00f6ssler, A. et al. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. Nature Communications 13, 7701 (2022). https:\/\/www.nature.com\/articles\/s41467-022-35312-3.","DOI":"10.1038\/s41467-022-35312-3"},{"key":"19578_CR30","doi-asserted-by":"crossref","unstructured":"Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022). https:\/\/www.nature.com\/articles\/s41586-022-04527-1. Publisher: Nature Publishing Group.","DOI":"10.1038\/s41586-022-04527-1"},{"key":"19578_CR31","doi-asserted-by":"crossref","unstructured":"Sokal, A. et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893\u20132907.e5 (2021). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761321003964.","DOI":"10.1016\/j.immuni.2021.09.011"},{"key":"19578_CR32","unstructured":"Kimura, I. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell 185, 3992\u20134007.e16 (2022). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0092867422011904."},{"key":"19578_CR33","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603 (2022)."},{"key":"19578_CR34","doi-asserted-by":"crossref","unstructured":"Neerukonda, S.\u00a0N. et al. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Journal of Virology 96, e01140\u201322 (2022). https:\/\/journals.asm.org\/doi\/full\/10.1128\/jvi.01140-22. Publisher: American Society for Microbiology.","DOI":"10.1128\/jvi.01140-22"},{"key":"19578_CR35","doi-asserted-by":"crossref","unstructured":"Twitchell, D.\u00a0K. et al. Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review. Androgens 3, 41\u201353 (2022). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9527649\/.","DOI":"10.1089\/andro.2022.0006"},{"key":"19578_CR36","doi-asserted-by":"crossref","unstructured":"Klein, S.\u00a0L. & Flanagan, K.\u00a0L. Sex differences in immune responses. Nature Reviews Immunology 16, 626\u2013638 (2016). https:\/\/www.nature.com\/articles\/nri.2016.90. Publisher: Nature Publishing Group.","DOI":"10.1038\/nri.2016.90"},{"key":"19578_CR37","doi-asserted-by":"crossref","unstructured":"Arnold, C.\u00a0G., Libby, A., Vest, A., Hopkinson, A. & Monte, A.\u00a0A. Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes. Biology of Sex Differences 13, 7 (2022). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8894555\/.","DOI":"10.1186\/s13293-022-00417-3"},{"key":"19578_CR38","doi-asserted-by":"crossref","unstructured":"Tao, K., Tzou, P.\u00a0L., Kosakovsky Pond, S.\u00a0L., Ioannidis, J. P.\u00a0A. & Shafer, R.\u00a0W. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Microbiology Spectrum 10, e00926\u201322 (2022). https:\/\/journals.asm.org\/doi\/full\/10.1128\/spectrum.00926-22. Publisher: American Society for Microbiology.","DOI":"10.1128\/spectrum.00926-22"},{"key":"19578_CR39","doi-asserted-by":"crossref","unstructured":"Metcalf, C. J.\u00a0E. et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet (London, England) 388, 728\u2013730 (2016). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5678936\/.","DOI":"10.1016\/S0140-6736(16)30164-7"},{"key":"19578_CR40","doi-asserted-by":"crossref","unstructured":"Nextstrain: real-time tracking of pathogen evolution | Bioinformatics | Oxford Academic. https:\/\/academic.oup.com\/bioinformatics\/article\/34\/23\/4121\/5001388?login=false.","DOI":"10.1093\/bioinformatics\/bty407"},{"key":"19578_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.15","volume":"5","author":"S Bhattacharya","year":"2018","unstructured":"Bhattacharya, S. et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Scientific Data 5, 180015 (2018).","journal-title":"Scientific Data"},{"key":"19578_CR42","unstructured":"Lorenc, T. et al. COVID-19: living map of the evidence (EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London., 2020). https:\/\/eppi.ioe.ac.uk\/cms\/Projects\/DepartmentofHealthandSocialCare\/Publishedreviews\/COVID-19Livingsystematicmapoftheevidence\/tabid\/3765\/Default.aspx."},{"key":"19578_CR43","doi-asserted-by":"crossref","unstructured":"Shackelford, G.\u00a0E. et al. Accumulating evidence using crowdsourcing and machine learning: A living bibliography about existential risk and global catastrophic risk. Futures 116, 102508 (2020). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0016328719303702.","DOI":"10.1016\/j.futures.2019.102508"},{"key":"19578_CR44","unstructured":"Ryan M. Hope<rmh3093@gmail.com>. Rmisc: Ryan Miscellaneous (2012). https:\/\/CRAN.R-project.org\/package=Rmisc. Institution: Comprehensive R Archive Network Pages: 1.5.1."},{"key":"19578_CR45","unstructured":"R\u00f6ssler, A. et al. BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants. medRxiv 2022.05.10.22274906 (2022). http:\/\/medrxiv.org\/content\/early\/2022\/05\/10\/2022.05.10.22274906.abstract."},{"key":"19578_CR46","unstructured":"Team, R.\u00a0C. R: A Language and Environment for Statistical Computing (2022). https:\/\/www.R-project.org\/."},{"key":"19578_CR47","doi-asserted-by":"crossref","unstructured":"Wilks, S.\u00a0H. Racmacs: Antigenic Cartography Macros (2022). https:\/\/acorg.github.io\/Racmacs\/.\u00a0","DOI":"10.32614\/CRAN.package.Racmacs"},{"key":"19578_CR48","unstructured":"Wilks, S.\u00a0H. _ablandscapes: Making Antibody landscapes Using R_ (2021). https:\/\/github.com\/acorg\/ablandscapes."},{"key":"19578_CR49","unstructured":"carolyn johnson [@Carolynyjohnson]. Pfizer-BioNtech data on omicron neutralization \u2013 showing that 2 doses vs. booster - along with beta\/delta https:\/\/t.co\/YUaAsUOqIh (2021). https:\/\/x.com\/Carolynyjohnson\/status\/1468583768961130501."},{"key":"19578_CR50","unstructured":"Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-announce-omicron-adapted-covid-19."},{"key":"19578_CR51","doi-asserted-by":"crossref","unstructured":"Cele, S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.08.21267417.","DOI":"10.1101\/2021.12.08.21267417"},{"key":"19578_CR52","doi-asserted-by":"crossref","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum (2021). https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.10.21267534v1.","DOI":"10.1016\/S0140-6736(21)02844-0"},{"key":"19578_CR53","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization \u2013 implications for control of the COVID-19 pandemic (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.12.472286.","DOI":"10.1101\/2021.12.12.472286"},{"key":"19578_CR54","doi-asserted-by":"crossref","unstructured":"Schmidt, F. et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.12.21267646.","DOI":"10.1101\/2021.12.12.21267646"},{"key":"19578_CR55","unstructured":"Joe Scholar [@JScholar]. @erlichya Here you go https:\/\/t.co\/Acu3mqWgsB (2021). https:\/\/x.com\/JScholar\/status\/1470110894856286216."},{"key":"19578_CR56","unstructured":"HKUMed-CU Medicine joint study finds COVID-19 variant Omicron significantly reduces virus neutralisation ability of BioNTech vaccine. https:\/\/www.med.hku.hk\/en\/news\/press\/20211212-omicron-avoids-killing-by-blood-serum."},{"key":"19578_CR57","doi-asserted-by":"crossref","unstructured":"Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.14.21267769.","DOI":"10.21203\/rs.3.rs-1168453\/v1"},{"key":"19578_CR58","unstructured":"Liu, L. et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2 (2021). https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.14.472719v1."},{"key":"19578_CR59","doi-asserted-by":"crossref","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.14.472630.","DOI":"10.1101\/2021.12.14.472630"},{"key":"19578_CR60","unstructured":"Doria-Rose, N.\u00a0A. et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.15.21267805."},{"key":"19578_CR61","doi-asserted-by":"crossref","unstructured":"Zhao, X. et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.16.472391.","DOI":"10.1101\/2021.12.16.472391"},{"key":"19578_CR62","doi-asserted-by":"crossref","unstructured":"Yu, X. et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.17.21267961.","DOI":"10.1101\/2021.12.17.21267961"},{"key":"19578_CR63","doi-asserted-by":"crossref","unstructured":"Carre\u00f1o, J.\u00a0M. et al. Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate (2021). https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.20.21268134v1. ISSN: 2126-8134 Pages: 2021.12.20.21268134.","DOI":"10.1101\/2021.12.20.21268134"},{"key":"19578_CR64","doi-asserted-by":"crossref","unstructured":"Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.20.473584.","DOI":"10.1101\/2021.12.20.473584"},{"key":"19578_CR65","unstructured":"Jacobsen, H. et al. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations ."},{"key":"19578_CR66","doi-asserted-by":"crossref","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.22.21268103.","DOI":"10.1101\/2021.01.18.426984"},{"key":"19578_CR67","unstructured":"Lusvarghi, S. et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.22.473880."},{"key":"19578_CR68","doi-asserted-by":"crossref","unstructured":"Haveri, A. et al. Neutralizing antibodies to SARS-CoV-2 Omicron variant after $$3^{{\\rm rd}}$$ mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.22.21268273.","DOI":"10.1101\/2021.12.22.21268273"},{"key":"19578_CR69","doi-asserted-by":"crossref","unstructured":"Ari\u00ebn, K.\u00a0K. et al. Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern (2021). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.23.21268316.","DOI":"10.1101\/2021.12.23.21268316"},{"key":"19578_CR70","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.24.474138.","DOI":"10.1101\/2021.12.24.474138"},{"key":"19578_CR71","doi-asserted-by":"crossref","unstructured":"Kotaki, R. et al. Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.24.474091.","DOI":"10.1101\/2021.12.24.474091"},{"key":"19578_CR72","doi-asserted-by":"crossref","unstructured":"Bekliz, M. et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nature Communications 13, 3840 (2022). https:\/\/www.nature.com\/articles\/s41467-022-31556-1.","DOI":"10.1038\/s41467-022-31556-1"},{"key":"19578_CR73","doi-asserted-by":"crossref","unstructured":"Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.12.28.474369.","DOI":"10.1101\/2021.12.28.474369"},{"key":"19578_CR74","doi-asserted-by":"crossref","unstructured":"Miyamoto, S. et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.28.21268481.","DOI":"10.1016\/j.medj.2022.02.006"},{"key":"19578_CR75","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.02.22268634.","DOI":"10.1101\/2022.01.02.22268634"},{"key":"19578_CR76","doi-asserted-by":"crossref","unstructured":"Van Der Straten, K. et al. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity 55, 1725\u20131731.e4 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761322003533.","DOI":"10.1016\/j.immuni.2022.07.018"},{"key":"19578_CR77","doi-asserted-by":"crossref","unstructured":"Medigeshi, G. et al. Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-months (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.04.22268747.","DOI":"10.1016\/j.ebiom.2022.103938"},{"key":"19578_CR78","unstructured":"Wang, L. et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines (2021). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.11.24.469906."},{"key":"19578_CR79","doi-asserted-by":"crossref","unstructured":"Lapa, D. et al. Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.15.22269335.","DOI":"10.1101\/2022.01.15.22269335"},{"key":"19578_CR80","doi-asserted-by":"crossref","unstructured":"Seidel, A. et al. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.17.22269201.","DOI":"10.1101\/2022.01.17.22269201"},{"key":"19578_CR81","doi-asserted-by":"crossref","unstructured":"Suntronwong, N. et al. COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.17.22269415.","DOI":"10.1101\/2022.01.17.22269415"},{"key":"19578_CR82","doi-asserted-by":"crossref","unstructured":"Xia, H. et al. Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine. bioRxiv 2022.01.21.476344 (2022). http:\/\/biorxiv.org\/content\/early\/2022\/01\/22\/2022.01.21.476344.abstract.","DOI":"10.1101\/2022.01.21.476344"},{"key":"19578_CR83","doi-asserted-by":"crossref","unstructured":"Pajon, R. et al. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine 386, 1088\u20131091 (2022). http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2119912.","DOI":"10.1056\/NEJMc2119912"},{"key":"19578_CR84","doi-asserted-by":"crossref","unstructured":"Wratil, P.\u00a0R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine 28, 496\u2013503 (2022). https:\/\/www.nature.com\/articles\/s41591-022-01715-4.","DOI":"10.1038\/s41591-022-01715-4"},{"key":"19578_CR85","doi-asserted-by":"crossref","unstructured":"Singh, J. et al. BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.28.22269990.","DOI":"10.15252\/rc.2022946475"},{"key":"19578_CR86","doi-asserted-by":"crossref","unstructured":"Yu, J. et al. Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.02.06.22270533.","DOI":"10.1101\/2022.02.06.22270533"},{"key":"19578_CR87","doi-asserted-by":"crossref","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022). https:\/\/www.nature.com\/articles\/s41586-022-04594-4.","DOI":"10.1038\/s41586-022-04594-4"},{"key":"19578_CR88","doi-asserted-by":"crossref","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022). https:\/\/www.nature.com\/articles\/s41586-021-04385-3.","DOI":"10.1038\/s41586-021-04385-3"},{"key":"19578_CR89","doi-asserted-by":"crossref","unstructured":"Peiris, M. et al. Virus neutralization of SARS-CoV-2 Omicron variant BA.2 in those vaccinated with three doses of BNT162b2 or CoronaVac vaccines. (2022). https:\/\/www.researchsquare.com\/article\/rs-1331606\/v1.","DOI":"10.21203\/rs.3.rs-1331606\/v1"},{"key":"19578_CR90","unstructured":"Yamasoba, D. et al. Virological characteristics of SARS-CoV-2 BA.2 variant (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.02.14.480335."},{"key":"19578_CR91","doi-asserted-by":"crossref","unstructured":"Mykytyn, A.\u00a0Z. et al. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Science Immunology 7, eabq4450 (2022). https:\/\/www.science.org\/doi\/10.1126\/sciimmunol.abq4450.","DOI":"10.1126\/sciimmunol.abq4450"},{"key":"19578_CR92","unstructured":"Kawaoka, Y. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron\/BA.2. Research Square rs.3.rs\u20131375091 (2022). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8887076\/."},{"key":"19578_CR93","unstructured":"Bowen, J.\u00a0E. et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 377, 890\u2013894 (2022). https:\/\/www.science.org\/doi\/10.1126\/science.abq0203."},{"key":"19578_CR94","doi-asserted-by":"publisher","unstructured":"Kurhade, C. et al. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes & Infections 11, 1828\u20131832 (2022). Publisher: Taylor & Francis _eprint: https:\/\/doi.org\/10.1080\/22221751.2022.2099305","DOI":"10.1080\/22221751.2022.2099305"},{"key":"19578_CR95","doi-asserted-by":"crossref","unstructured":"Richardson, S.\u00a0I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host & Microbe 30, 880\u2013886.e4 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312822001597.","DOI":"10.1016\/j.chom.2022.03.029"},{"key":"19578_CR96","doi-asserted-by":"crossref","unstructured":"Chen, L.-L., Chu, A. W.-H., Zhang, R. R.-Q., Hung, I. F.-N. & To, K. K.-W. Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2. The Lancet Microbe 3, e404 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266652472200060X.","DOI":"10.1016\/S2666-5247(22)00060-X"},{"key":"19578_CR97","unstructured":"Rose, R. et al. Delta or Omicron BA.1\/2-neutralizing antibody levels and T-cell reactivity after triple-vaccination or infection (2022). https:\/\/www.authorea.com\/users\/467757\/articles\/561708-delta-or-omicron-ba-1-2-neutralizing-antibody-levels-and-t-cell-reactivity-after-triple-vaccination-or-infection?commit=6538dc4d7da3d942d3fe4b2580cf6581e6c28f06."},{"key":"19578_CR98","doi-asserted-by":"crossref","unstructured":"Zou, J. et al. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 (2022). https:\/\/www.biorxiv.org\/content\/10.1101\/2022.03.30.486409v1.","DOI":"10.1101\/2022.03.30.486409"},{"key":"19578_CR99","doi-asserted-by":"crossref","unstructured":"Marking, U. et al. Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.04.02.22273333.","DOI":"10.1101\/2022.04.02.22273333"},{"key":"19578_CR100","doi-asserted-by":"crossref","unstructured":"Gruell, H. et al. Delineating antibody escape from Omicron sublineages (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.04.06.487257.","DOI":"10.1101\/2022.04.06.487257"},{"key":"19578_CR101","doi-asserted-by":"crossref","unstructured":"Arora, P. et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. The Lancet Infectious Diseases 22, 766\u2013767 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309922002249.","DOI":"10.1016\/S1473-3099(22)00224-9"},{"key":"19578_CR102","doi-asserted-by":"crossref","unstructured":"Stiasny, K. et al. Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization (2022). https:\/\/www.researchsquare.com\/article\/rs-1536794\/v1.","DOI":"10.21203\/rs.3.rs-1536794\/v1"},{"key":"19578_CR103","doi-asserted-by":"crossref","unstructured":"Evans, J.\u00a0P. et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host & Microbe 30, 1093\u20131102.e3 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312822002207.","DOI":"10.1016\/j.chom.2022.04.014"},{"key":"19578_CR104","doi-asserted-by":"crossref","unstructured":"Khan, K. et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature 607, 356\u2013359 (2022). https:\/\/www.nature.com\/articles\/s41586-022-04830-x.","DOI":"10.1038\/s41586-022-04830-x"},{"key":"19578_CR105","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.04.30.489997."},{"key":"19578_CR106","doi-asserted-by":"crossref","unstructured":"Ai, J. et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host & Microbe 30, 1077\u20131083.e4 (2022). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1931312822002438.","DOI":"10.1016\/j.chom.2022.05.001"},{"key":"19578_CR107","doi-asserted-by":"crossref","unstructured":"Arora, P. et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host & Microbe 30, 1103\u20131111.e6 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312822002232.","DOI":"10.1016\/j.chom.2022.04.017"},{"key":"19578_CR108","unstructured":"Khan, K. et al. Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nature Communications 13, 4686 (2022). https:\/\/www.nature.com\/articles\/s41467-022-32396-9."},{"key":"19578_CR109","doi-asserted-by":"crossref","unstructured":"Qu, P. et al. Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4\/5 and BA.2.12.1 Subvariants (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.05.16.492158.","DOI":"10.1101\/2022.05.16.492158"},{"key":"19578_CR110","doi-asserted-by":"crossref","unstructured":"Hachmann, N.\u00a0P. et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. New England Journal of Medicine 387, 86\u201388 (2022). http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2206576.","DOI":"10.1056\/NEJMc2206576"},{"key":"19578_CR111","doi-asserted-by":"crossref","unstructured":"Zhou, J. et al. Omicron breakthrough infections in vaccinated or previously infected hamsters (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.05.20.492779.","DOI":"10.1073\/pnas.2308655120"},{"key":"19578_CR112","unstructured":"Tuekprakhon, A. et al. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.05.21.492554."},{"key":"19578_CR113","doi-asserted-by":"crossref","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5 (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.05.26.493517.","DOI":"10.1101\/2022.05.26.493517"},{"key":"19578_CR114","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.05.498883.","DOI":"10.1101\/2022.07.05.498883"},{"key":"19578_CR115","doi-asserted-by":"crossref","unstructured":"Aggarwal, A. et al. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern (2022). http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.07.07.22277128.","DOI":"10.2139\/ssrn.4157473"},{"key":"19578_CR116","unstructured":"Cao, Y. et al. Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75 (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.18.500332."},{"key":"19578_CR117","doi-asserted-by":"crossref","unstructured":"Sheward, D.\u00a0J. et al. Evasion of neutralizing antibodies by Omicron sublineage BA.2.75 (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.19.500716.","DOI":"10.1101\/2022.07.19.500716"},{"key":"19578_CR118","doi-asserted-by":"crossref","unstructured":"Qu, P. et al. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4\/5 Variants (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.21.501010.","DOI":"10.1101\/2022.07.21.501010"},{"key":"19578_CR119","doi-asserted-by":"crossref","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.07.29.502055.","DOI":"10.1101\/2022.07.29.502055"},{"key":"19578_CR120","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host & Microbe 30, 1745\u20131758.e7 (2022). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193131282200525X.","DOI":"10.1016\/j.chom.2022.10.012"},{"key":"19578_CR121","doi-asserted-by":"crossref","unstructured":"Muik, A. et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4\/BA.5 (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.02.502461.","DOI":"10.1101\/2022.08.02.502461"},{"key":"19578_CR122","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Neutralization of Omicron BA.4\/BA.5 and BA.2.75 by Booster Vaccination or BA.2 Breakthrough Infection Sera (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.04.502716.","DOI":"10.1101\/2022.08.04.502716"},{"key":"19578_CR123","doi-asserted-by":"crossref","unstructured":"Gruell, H. et al. Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.04.502609.","DOI":"10.1101\/2022.08.04.502609"},{"key":"19578_CR124","doi-asserted-by":"crossref","unstructured":"Qu, P. et al. Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.14.503921.","DOI":"10.1101\/2022.08.14.503921"},{"key":"19578_CR125","doi-asserted-by":"crossref","unstructured":"Yu, X. et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discovery 8, 4 (2022). https:\/\/www.nature.com\/articles\/s41421-022-00375-5. Publisher: Nature Publishing Group.","DOI":"10.1038\/s41421-022-00375-5"},{"key":"19578_CR126","doi-asserted-by":"crossref","unstructured":"Zhao, X. et al. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. New England Journal of Medicine 386, 894\u2013896 (2022). https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2119426. Publisher: Massachusetts Medical Society _eprint: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2119426","DOI":"10.1056\/NEJMc2119426"},{"key":"19578_CR127","doi-asserted-by":"crossref","unstructured":"Gruell, H. et al. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host & Microbe 30, 1231\u20131241.e6 (2022). https:\/\/www.cell.com\/cell-host-microbe\/abstract\/S1931-3128(22)00318-3. Publisher: Elsevier.","DOI":"10.1016\/j.chom.2022.07.002"},{"key":"19578_CR128","doi-asserted-by":"crossref","unstructured":"Kurhade, C. et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine (2022). http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.03.24.485633.","DOI":"10.1101\/2022.03.24.485633"},{"key":"19578_CR129","doi-asserted-by":"crossref","unstructured":"Medits, I. et al. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. Frontiers in Immunology 13 (2022). https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2022.946318\/full. Publisher: Frontiers.","DOI":"10.3389\/fimmu.2022.946318"},{"key":"19578_CR130","doi-asserted-by":"crossref","unstructured":"Cao, Y. et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host & Microbe 30, 1527\u20131539.e5 (2022). https:\/\/www.cell.com\/cell-host-microbe\/abstract\/S1931-3128(22)00511-X. Publisher: Elsevier.","DOI":"10.1016\/j.chom.2022.09.018"},{"key":"19578_CR131","unstructured":"Kassambara, A. _rstatix: Pipe-Friendly Framework for Basic Statistical Tests_ (2023). https:\/\/CRAN.R-project.org\/package=rstatix."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19578-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:24:43Z","timestamp":1761294283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19578-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19578"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19578-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37193"}}